Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has provided an update.
Sinopharm Group Co. Ltd. announced the composition of its board of directors, detailing the roles and functions of each member. The announcement highlights the company’s governance structure, with a focus on the various board committees and their respective members. This update may impact the company’s strategic direction and governance, influencing stakeholders’ perceptions and the company’s industry positioning.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the healthcare industry, focusing on pharmaceuticals and medical devices. It is a prominent player in the Chinese market, providing a wide range of healthcare products and services.
Average Trading Volume: 7,668,891
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.57B
Find detailed analytics on 1099 stock on TipRanks’ Stock Analysis page.